TCE-A / Jiangsu Hengrui Pharma - LARVOL DELTA

TCE-A: An "OR-gate" CD19×CD20×CD3 trispecific T-cell engager for B-cell malignancies and autoimmune diseases (AACR 2026) - "TCE-A also exhibits excellent stability and developability, suitable for subcutaneous administration, which may potentially mitigate treatment-related toxicities, particularly cytokine release syndrome in the clinical setting.In summary, TCE-A demonstrates potent dual-target activity against B-cell malignancies and autoimmune disease models. Its rituximab-compatible epitope, high efficacy and differentiated pharmacokinetic/developability, warrant further clinical development for B-NHL and autoimmune indications."

Late-breaking abstract • Trispecific • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20